This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta

This blows Rexahn's claims of positive Archexin results out of the water. The 9.1-month median survival isn't real. Don't believe the data for a second.






@SCarolinaguy asks, "Of all the drugs approved or going through approval this year, which single one do you think will bring the most benefit to a patient?"

That's a really interesting question and one I don't think about often because I'm so focused on the investing, stock price, revenue potential, etc. side of things. It's also a difficult question to answer because benefit can be so subjective. Any drug that helps a patient is the most beneficial to them.

My choice for the most beneficial drug approved this year is Kalydeco, the cystic fibrosis drug developed by Vertex Pharmaceuticals (VRTX - Get Report). Kalydeco represents groundbreaking science that tackles the root cause of cystic fibrosis for the first time instead of just ameliorating the disease's symptoms. FDA approved Kalydeco in January.

I asked the Twitterverse to weigh in on their selection. Some people voted for eteplirsen, the Duchenne muscular dystrophy drug from Sarepta Therapeutics (SRPT - Get Report). A good choice but perhaps a bit premature since eteplirsen isn't approved yet and no one is really sure whether the data will allow Sarepta to file for early approval later this year.

Other nominees included Menhibrix, a meningococcal disease vaccine from GlaxoSmithKline (GSK); Vascepa, the lipid-lowering prescription fish-oil pill from Amarin (AMRN); and naturally (although undeservingly) the obesity pills Belviq and Qsymia from Arena Pharmaceuticals (ARNA - Get Report) and Vivus (VVUS), respectively.

The question does allow for drugs are not yet approved buy may be before year's end. In this category, the blood-thinner Eliquis from Pfizer (PFE) and Bristol-Myers Squibb (BMY) deserves consideration, says one Twitter follower. "Not as dramatic a benefit as Kalydeco but affects many more patients. Warfarin is a b--ch," he says.

Am I missing a truly beneficial new drug approved this year? Let me know.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARNA $4.19 0.00%
PPHM $1.32 0.00%
RNN $0.72 0.00%
SRPT $26.22 0.00%
VRTX $125.08 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs